USP25 and Cognitive impairment: Genetic deletion or pharmacological inhibition of USP25 enhances Aβ-induced synapse phagocytosis, restores microglial homeostasis, and reduces neuroinflammation and cognitive impairment in AD mice, highlighting USP25 as a promising therapeutic target for AD.